SCHEMBL14714513

SCHEMBL14714513

Cn1cc(CNC(=O)C(NC(=O)c2ccc(-c3ccc(OCCO)cc3)cc2)C(=O)NO)cn1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
EGLN2 Q96KS0 1/20 0.39
PPARG P37231 1/20 0.39
ROCK2 O75116 1/20 0.39
CLK1 P49759 2/20 0.39
KLKB1 P03952 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM1A O60341 1/20 0.38
HDAC1 Q13547 1/20 0.38
GAA P10253 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14715042 0.83 LMNA (0.54) ROCK2SMN1; SMN2
SCHEMBL14714737 0.83 KLKB1 (0.51) MEN1KMT2AROCK2KLKB1KDM1A
SCHEMBL14715281 0.83 HRH3 (0.42) HRH3KMT2APPARGROCK2KLKB1
SCHEMBL14714539 0.83 HPGDS (0.42) HRH3HSD17B10PPARGROCK2ALDH1A1
SCHEMBL14715019 0.83 HRH3 (0.42) HRH3HSD17B10EGLN2PPARGALDH1A1
SCHEMBL14715228 0.81 HRH3 (0.41) HRH3PPARGROCK2SMN1; SMN2GAA
SCHEMBL14715195 0.81 TSHR (0.57) MEN1KMT2AROCK2SMN1; SMN2HDAC1
SCHEMBL14715049 0.81 PPARG (0.51) HRH3PPARGGAA
SCHEMBL14715425 0.80 PPARG (0.50) HRH3MEN1KMT2APPARG
SCHEMBL14714981 0.79 ANPEP (0.49) HRH3PPARGGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2562155-B1 HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2019-06-05 EP disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 HRH3 1334/4885MEN1 4264/4885KMT2A 361/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 HRH3 1334/4885MEN1 4264/4885KMT2A 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.